Abstract
A pilot study was undertaken in eight patients to assess the feasibility of recombinant human granulocyte-macrophage colony-stimulating factor (rH GM-CSF) support to intensify standard chemotherapy for advanced ovarian cancer using a shortened 15 day treatment interval. Only four patients completed the course of six cycles of cisplatin 75 mg m-2 and cyclophosphamide 750 mg m-2 with rH GM-CSF, 3-5 micrograms kg-1 day-1, days 3-14, but one of these suffered a toxic death on study. Another died of disease progression. There were two episodes of life-threatening infection (WHO grade 4), and three patients were withdrawn because of various rH GM-CSF-related problems. Although potentially affording some patients the hypothetical benefits of dose intensification, as well as the possible attraction of a shorter duration of chemotherapy, this regimen is not without problems.
Publication types
-
Clinical Trial
-
Clinical Trial, Phase I
-
Clinical Trial, Phase II
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / mortality
-
Adenocarcinoma / pathology
-
Adenocarcinoma, Mucinous / drug therapy
-
Adenocarcinoma, Mucinous / mortality
-
Adenocarcinoma, Mucinous / pathology
-
Adult
-
Aged
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Cisplatin / administration & dosage
-
Cisplatin / adverse effects
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Feasibility Studies
-
Female
-
Granulocyte-Macrophage Colony-Stimulating Factor / therapeutic use*
-
Granulocyte-Macrophage Colony-Stimulating Factor / toxicity*
-
Humans
-
Middle Aged
-
Neoplasm Staging
-
Ovarian Neoplasms / drug therapy*
-
Ovarian Neoplasms / mortality
-
Ovarian Neoplasms / pathology
-
Recombinant Proteins / therapeutic use
-
Recombinant Proteins / toxicity
-
Survival Rate
Substances
-
Recombinant Proteins
-
Granulocyte-Macrophage Colony-Stimulating Factor
-
Cyclophosphamide
-
Cisplatin